Welcome to our dedicated page for Firefly Neuroscience SEC filings (Ticker: AIFF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Firefly Neuroscience, Inc. filings document the public-company disclosures of an AI precision-neuroscience business focused on EEG/ERP brain analytics and related software platforms. Its Form 8-K reports cover material financing agreements, including securities purchase agreements for unit issuances and at-the-market common stock sales arrangements, along with corporate events affecting its capital structure.
Proxy and annual meeting filings describe Firefly Neuroscience governance matters, including director elections, auditor ratification, incentive plan amendments, common stock voting mechanics and stockholder vote results. The filing record also provides formal disclosure context for the company’s operating model, commercialization activities, equity plan administration and governance obligations as a Nasdaq-listed Delaware corporation.
Firefly Neuroscience (AIFF): A reporting group led by Windsor Private Capital disclosed open‑market sales of common stock under Rule 144. On 10/20/2025 they sold 33,500 shares at $2.457; on 10/21/2025 they sold 19,222 shares at $2.4004; and on 10/22/2025 they sold 78,031 shares at $2.0727.
Following these transactions, the group states it is no longer a beneficial owner of more than 10% of the company’s securities. After the final sale, 1,236,773 shares were beneficially owned indirectly, held through Windsor, per the filing footnotes.
Firefly Neuroscience (AIFF) insiders reported open‑market sales by a group affiliated with Windsor Private Capital. On 10/15/2025, 17,500 shares were sold at an average price of $2.7444; on 10/16/2025, 40,139 shares at $2.6522; and on 10/17/2025, 45,036 shares at $2.5462. Following these transactions, the group reported 1,452,701, then 1,412,562, and finally 1,367,526 shares beneficially owned. The filing notes these sales were conducted under Rule 144 and that the holdings are reported as indirectly owned through Windsor, with the reporting persons identified as members of a group that beneficially owns more than 10%.
Firefly Neuroscience (AIFF): insider group reports open-market sales
A group of reporting persons led by Windsor Private Capital LP, identified as more than 10% beneficial owners, disclosed multiple sales of Firefly Neuroscience common stock under Rule 144. Reported transactions include sales on 10/09/2025 (30,126 shares at $2.9441), 10/10/2025 (74,810 shares at $2.6994), 10/13/2025 (32,136 shares at $2.6525), and 10/14/2025 (29,500 shares at $2.739). Following these trades, the group reports 1,470,201 shares beneficially owned indirectly.
The securities are held by Windsor; related entities and individuals (including WPC entities and certain officers) may be deemed beneficial owners, with stated disclaimers of beneficial ownership except to the extent of pecuniary interest.
Firefly Neuroscience, Inc. (AIFF) notice shows a proposed sale of 74,810 common shares to be executed through Haywood Securities Inc. on 10/10/2025 on NASDAQ, with an aggregate market value of $201,939.87. The shares were acquired by the selling party on 08/12/2024 as merger consideration, totaling 1,636,990 shares received at that time. The filer reports one sale in the prior three months: 30,126 shares sold on 10/09/2025 for gross proceeds of $86,694.86. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Firefly Neuroscience (AIFF) filed a Form 144 notifying the proposed sale of 30,126 shares of common stock, scheduled to be sold on 10/09/2025 on NASDAQ. The filing lists an aggregate market value of $86,694.86 for the shares and shows 13,448,848 shares outstanding, making the block roughly 0.224% of the outstanding stock. The securities were acquired on 08/12/2024 as merger consideration, with 1,636,990 shares received in that transaction. No securities were reported sold by the same person in the past three months. The filer certifies they are not aware of undisclosed material adverse information.
Firefly Neuroscience, Inc. (AIFF) is soliciting proxies for its 2025 Annual Meeting to be held virtually at 10:00 a.m. ET on October 27, 2025. The Board recommends votes FOR five proposals: elect two Class II directors (nominees Brian Posner and Stella Vnook), ratify appointment of Marcum as independent auditor for fiscal 2025, approve an amendment to the equity incentive plan to add 317,820 shares and an annual automatic increase (lower of 4% of outstanding common stock or Board-determined amount) from January 1, 2026 through January 1, 2035, authorize the Board to increase authorized shares up to an aggregate of 5,001,000,000 (including 1,000,000 preferred shares), and allow adjournment if needed to solicit additional proxies. Materials including the 2024 Form 10-K are available at www.proxyvote.com and the virtual meeting website. The proxy describes Board composition, committee charters, indemnification and director compensation (option awards for non-employee directors), and discloses pay-versus-performance information noting that net loss increased from 2023 to 2024 while compensation actually paid (CAP) to NEOs increased. Voting methods (Internet, mail, virtual) and quorum/broker-vote rules are explained.
Firefly Neuroscience, Inc. has issued a preliminary proxy for its virtual 2025 Annual Meeting to be held October 31, 2025. The Board recommends five proposals: elect two Class II directors to three-year terms ending 2028; ratify Marcum as independent auditor for fiscal 2025; approve Amendment No. 1 to the equity incentive plan to add 317,820 shares and provide annual automatic increases (up to 4% of outstanding shares) from January 1, 2026 through January 1, 2035; authorize the Board to increase authorized shares from 101,000,000 to up to 5,001,000,000 (including 1,000,000 preferred); and permit adjournment if needed to solicit votes. The proxy discloses board composition, committee charters, related-person transaction review procedures, indemnification and insurance, and executive compensation summary including pay-versus-performance tables and narrative. Proxy materials and the 2024 Form 10-K are available at the links provided.
Firefly Neuroscience, Inc. has issued a preliminary proxy for its virtual 2025 Annual Meeting to be held October 31, 2025. The Board recommends five proposals: elect two Class II directors to three-year terms ending 2028; ratify Marcum as independent auditor for fiscal 2025; approve Amendment No. 1 to the equity incentive plan to add 317,820 shares and provide annual automatic increases (up to 4% of outstanding shares) from January 1, 2026 through January 1, 2035; authorize the Board to increase authorized shares from 101,000,000 to up to 5,001,000,000 (including 1,000,000 preferred); and permit adjournment if needed to solicit votes. The proxy discloses board composition, committee charters, related-person transaction review procedures, indemnification and insurance, and executive compensation summary including pay-versus-performance tables and narrative. Proxy materials and the 2024 Form 10-K are available at the links provided.